bevacizumab
Ovarian Cancer Patients Without BRCA Mutations Benefit From Lynparza, Imfinzi Plus Standard of Care
Premium
Data presented at ASCO suggests that patients with BRCA-wild type tumors could benefit from a regimen comprising the PARP and checkpoint inhibitors added to chemo and Avastin.
NICE Backs Merck's Keytruda for PD-L1-Expressing Cervical Cancer
NICE recommended that Keytruda plus chemo with or without Avastin be available in England for cervical cancers expressing PD-L1 with a combined positive score of at least 1.
Lynparza Presents Possibility of Cure for Some Patients With Biomarker-Defined Ovarian Cancer
Premium
Data from two Phase III studies showed at ESMO that patients with BRCA1/2 mutations and HRD are living longer with maintenance therapy with Lynparza alone and in combination with Avastin.
However, in the Phase III PARADIGM trial, there was no difference in survival between the two arms when researchers focused only on patients with right-sided tumors.
FDA Approves First-Line Keytruda Combo for PD-L1-Expressing Cervical Cancer Patients
The agency approved Keytruda as a front-line option with chemo, with or without Avastin, and converted a second-line accelerated approval for the immunotherapy to full approval.